Wall Street brokerages predict that Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) will post earnings per share (EPS) of ($3.39) for the current fiscal quarter, Zacks reports. Six analysts have provided estimates for Intercept Pharmaceuticals’ earnings, with estimates ranging from ($4.29) to ($2.11). Intercept Pharmaceuticals reported earnings of ($4.84) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 30%. The firm is scheduled to announce its next earnings report on Thursday, February 22nd.

On average, analysts expect that Intercept Pharmaceuticals will report full year earnings of ($13.34) per share for the current year, with EPS estimates ranging from ($14.26) to ($12.07). For the next financial year, analysts forecast that the company will report earnings of ($12.26) per share, with EPS estimates ranging from ($15.66) to ($8.15). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that that provide coverage for Intercept Pharmaceuticals.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($3.48) by $0.59. The business had revenue of $41.33 million for the quarter, compared to the consensus estimate of $36.95 million. Intercept Pharmaceuticals had a negative return on equity of 176.51% and a negative net margin of 344.74%. The firm’s quarterly revenue was up 697.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($3.59) earnings per share.

A number of equities research analysts recently issued reports on ICPT shares. Wedbush reissued a “buy” rating on shares of Intercept Pharmaceuticals in a research report on Monday, July 31st. BidaskClub raised Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 24th. Jefferies Group LLC reissued a “buy” rating and set a $275.00 price target on shares of Intercept Pharmaceuticals in a research report on Sunday, July 30th. Cowen and Company reissued a “buy” rating and set a $112.00 price target (down previously from $232.00) on shares of Intercept Pharmaceuticals in a research report on Friday, September 22nd. Finally, Seaport Global Securities restated a “buy” rating and set a $136.00 target price on shares of Intercept Pharmaceuticals in a research note on Friday, October 6th. Three analysts have rated the stock with a sell rating, ten have assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $144.41.

In related news, CEO Mark Pruzanski sold 1,532 shares of the firm’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $58.87, for a total transaction of $90,188.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Lisa Bright sold 253 shares of the firm’s stock in a transaction on Friday, August 25th. The stock was sold at an average price of $111.31, for a total value of $28,161.43. Following the transaction, the insider now directly owns 23,324 shares of the company’s stock, valued at $2,596,194.44. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 4,069 shares of company stock valued at $325,974. 4.50% of the stock is owned by corporate insiders.

A number of large investors have recently made changes to their positions in ICPT. Public Employees Retirement Association of Colorado grew its holdings in Intercept Pharmaceuticals by 1.1% during the 2nd quarter. Public Employees Retirement Association of Colorado now owns 4,111 shares of the biopharmaceutical company’s stock worth $498,000 after acquiring an additional 43 shares during the period. Janney Montgomery Scott LLC grew its holdings in Intercept Pharmaceuticals by 1.8% during the 2nd quarter. Janney Montgomery Scott LLC now owns 3,435 shares of the biopharmaceutical company’s stock worth $416,000 after acquiring an additional 62 shares during the period. WFG Advisors LP grew its holdings in Intercept Pharmaceuticals by 16.4% during the 2nd quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock worth $108,000 after acquiring an additional 125 shares during the period. Utah Retirement Systems grew its holdings in Intercept Pharmaceuticals by 6.5% during the 2nd quarter. Utah Retirement Systems now owns 3,300 shares of the biopharmaceutical company’s stock worth $400,000 after acquiring an additional 200 shares during the period. Finally, State of Wisconsin Investment Board grew its holdings in Intercept Pharmaceuticals by 7.9% during the 2nd quarter. State of Wisconsin Investment Board now owns 3,567 shares of the biopharmaceutical company’s stock worth $432,000 after acquiring an additional 260 shares during the period. 76.62% of the stock is owned by institutional investors and hedge funds.

Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) traded up $0.44 during trading hours on Wednesday, reaching $62.24. The company had a trading volume of 490,209 shares, compared to its average volume of 776,591. Intercept Pharmaceuticals has a 1-year low of $54.98 and a 1-year high of $135.59. The company has a debt-to-equity ratio of 3.15, a quick ratio of 5.95 and a current ratio of 5.95.

ILLEGAL ACTIVITY NOTICE: “Zacks: Analysts Anticipate Intercept Pharmaceuticals, Inc. (ICPT) to Post -$3.39 EPS” was reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://www.watchlistnews.com/zacks-analysts-anticipate-intercept-pharmaceuticals-inc-icpt-to-post-3-39-eps/1720411.html.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Get a free copy of the Zacks research report on Intercept Pharmaceuticals (ICPT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.